Bristol-Myers Squibb Co. (NYSE:BMY)’s share price reached a new 52-week high during trading on Friday . The company traded as high as $75.23 and last traded at $74.94, with a volume of 2,151,535 shares traded. The stock had previously closed at $74.08.

A number of equities research analysts have issued reports on the company. Jefferies Group raised their target price on Bristol-Myers Squibb from $76.00 to $78.00 and gave the company a “hold” rating in a research note on Tuesday, June 14th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Bristol-Myers Squibb in a research note on Thursday, May 19th. Berenberg Bank reiterated a “buy” rating and issued a $80.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, April 22nd. Leerink Swann reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, April 27th. Finally, Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $70.88 target price on the stock in a research note on Wednesday, March 16th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $73.79.

The firm has a market cap of $125.67 billion and a P/E ratio of 80.86. The firm’s 50-day moving average is $72.33 and its 200-day moving average is $67.32.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.09. During the same period in the prior year, the firm posted $0.71 EPS. The business earned $4.39 billion during the quarter, compared to analyst estimates of $4.19 billion. Bristol-Myers Squibb’s revenue for the quarter was up 8.7% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb Co. will post $2.56 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be paid a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a yield of 2.02%. The ex-dividend date of this dividend is Wednesday, June 29th.

In other news, SVP John E. Elicker sold 11,820 shares of the company’s stock in a transaction on Tuesday, June 14th. The stock was sold at an average price of $72.69, for a total transaction of $859,195.80. Following the transaction, the senior vice president now owns 55,011 shares of the company’s stock, valued at $3,998,749.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Autenried Paul Von sold 37,258 shares of the company’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $71.93, for a total value of $2,679,967.94. Following the transaction, the senior vice president now directly owns 128,463 shares in the company, valued at approximately $9,240,343.59. The disclosure for this sale can be found here.

Several institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Bristol-Myers Squibb by 8.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,135,086 shares of the biopharmaceutical company’s stock valued at $146,884,000 after buying an additional 164,657 shares during the period. Dorsey & Whitney Trust CO LLC raised its position in shares of Bristol-Myers Squibb by 1.9% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 30,580 shares of the biopharmaceutical company’s stock valued at $2,104,000 after buying an additional 556 shares during the period. Jennison Associates LLC raised its position in shares of Bristol-Myers Squibb by 19.2% in the fourth quarter. Jennison Associates LLC now owns 27,739,860 shares of the biopharmaceutical company’s stock valued at $1,908,225,000 after buying an additional 4,462,075 shares during the period. Westbourne Investment Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 2.3% in the fourth quarter. Westbourne Investment Advisors Inc. now owns 29,440 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 650 shares during the period. Finally, Homrich & Berg raised its position in shares of Bristol-Myers Squibb by 3.8% in the fourth quarter. Homrich & Berg now owns 18,171 shares of the biopharmaceutical company’s stock valued at $1,250,000 after buying an additional 671 shares during the period.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.